A retrospective cohort study of patients with stomach and liver cancers: the impact of comorbidity and ethnicity on cancer care and outcomes

Table 3 Association between comorbidity and treatment receipt among stage I-III patients: unadjusted and adjusted odds ratios

Impact of comorbidity evaluated at C3 score of:*	Unadjusted OR (95% CI)	Adj OR ** (95% CI)
0	1.00	1.00
1	0.70 (0.50-0.98)	0.92 (0.59-1.42)
2	0.53 (0.31-0.89)	0.80 (0.40-1.6)
3	0.42 (0.23-0.78)	0.66 (0.29-1.49)
6	0.29 (0.15-0.56)	0.32 (0.13-0.78)

* evaluation of the OR at a score of 1, 2, 3 and 6 (in relation to a score of 0). No results are presented beyond 6 as the 95^th percentile of the C3 Index score distribution was 6.74, which means estimates of the OR beyond this point on the scale are of limited utility.
** adjusted for age (continuous), sex, site (stomach/ liver), stage (I, II, III), deprivation (continuous, in deciles), rurality (rural/other), ethnicity (Māori/ Non-Māori).

ISSN: 1471-2407